CA-SYNACK
6.6.2019 17:02:17 CEST | Business Wire | Press release
Today, Synack, the most trusted crowdsourced security testing platform and top choice of major enterprises and governments, becomes the only crowdsourced penetration testing company to offer secure and managed workspaces with endpoint control. LaunchPoint+ extends Synack’s original LaunchPoint VPN offering by providing a managed workspace environment for crowdsourced testing of enterprise and government assets.
In the midst of calls for greater consumer privacy from the European Commission to Apple, and states like NY and CA introducing bold privacy bills, Synack is launching their new LaunchPoint+ product to help organizations meet today’s rising security standards. Just as Apple now provides privacy-as-a-service (PaaS) to accommodate consumer privacy demands in their latest iOS upgrade, Synack is providing additional privacy and data control to its customers.
As GDPR, HIPAA, PCI-DSS and ISO 27001 require increasingly stringent requirements for data privacy, Synack has developed a new offering to help meet, and in some cases exceed, what is required. In use cases that require extra care (such as where PII data is involved), consumers and regulators alike are increasingly demanding more attention for data privacy. A violation of GDPR could result in a fine of up to 4% of annual revenue, incentivizing organizations to protect the data in their care.
Many organizations, both governments and enterprises, are held to regulatory standards that demand heightened requirements around privacy. For others such as Apple, enforcement of privacy is a way to develop more trust with their customers and differentiate their brands. In a recent survey by SAS, 73% of consumers said their concerns over data privacy were increasing. Synack has responded by providing managed workspaces with endpoint controls to give these organizations the data protection and privacy environment during the testing period that they need.
As the leader of crowdsourced security, Synack has continuously brought to market new technology features that build, measure, and demonstrate trust between enterprises and their customers, and organizations and ethical hackers. Through innovations like the Attacker Resistance Score, Coverage Analytics, Trust Report, and Guardians of Trust Awards, Synack has put the trust and privacy of its customers first. LaunchPoint+ is another example of that commitment.
For Synack customers, the company’s new workspace will enable endpoint control, data privacy objectives, and improved trust between customers and researchers.
“We’ve set out to build trust between organizations and ethical hackers since our founding in 2013. We’re really excited to continue enhancing the Synack platform with technology feature updates like LaunchPoint+, because these are what give customers more control and make the crowdsourced testing model more trusted,” Synack CTO and co-founder Mark Kuhr said.
“The ability to have enhanced security controls directly applied to the attack workstation will help ensure data privacy and compliance requirements are met and consistently enforced,” says David Charlton, former Head of Penetration Testing at J.P. Morgan Chase & Co, and Synack’s Head of Product Strategy.
For Synack Red Team researchers, LaunchPoint+ will eradicate the need to manually connect to a VPN server and ensure a stable connection with reduced network latency. When asked for feedback, Synack Red Team researchers said they were “happy with the concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot.”
As more security teams move towards crowdsourced penetration testing, Synack leads the way in trust by offering features like LaunchPoint+ that ensure private, safe and controlled testing.
About Synack
Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005487/en/
Contact:
Ellie McCardwell press@synack.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
